维普期刊资源整合服务平台（V6.5）

39篇 您的检索式：作者名="Dark G"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Landscape change and habitat availability in the southern highlands and Olympic Peninsula显示文摘	Pearson S M Turner M G Darke J B	1999	Ecological Applications1999，9，4：	1
2	Estimation of time varying skewness and kurtosis with an application to value-at-risk显示文摘	Dark J G		0，，03：	1
3	Estimation of time varying skewness and kurtosis with an application to value at risk 显示文摘	Dark J G	2010	Studies in Nonlinear Dynamics & Econometrics2010，14，2：	1
4	Acutehemodynamic effects of intravenous silde-nafil citrate in congestive heart failure:comparison of phosphodiesterase type -3and -5 inhibition 显示文摘	Botha P Parry G Dark JH	2009	J Heart LungTransplant2009，287，：	1
5	Pemetrexed combined with oxalip latin or carbop latin as first2line treatment in advanced non-small cell lung cancer:a multicenter,randomized Phase Ⅱ trail显示文摘	Scagliotti G Kortsik C Dark GG	2005	Clin Cancer Res2005，11，21：	1
6	Photoperiodic regulation of body mass food intake and reproduction in meadow voles 显示文摘	Dark J Zucker I Wade G N	1983	Am J Physiol-Reg I1983，245，：	1
7	Pemerexed combined with oxaliplatin or carbopl at in as first line treatment in advanced non-small cell lung cancer: a multieenter, randomized, phase I1 tri- al显示文摘	Scagliotti G V Kortsik C Dark G G	2005	Clin Cancer Res2005，15，11：	1
8	Single-agent pemetrexedfor chemonaive and pretreated patients with malignant pleuralmesothelioma:results of an International Expanded Access Pro-gram显示文摘	Taylor P Castagneto B Dark G	2008	J Thorac Oncol2008，3，7：	1
9	Stakeholder viewpoints in requirements definition: A framework for understanding viewpoint de- velopment approaches显示文摘	Darke P Shanks G	1996	Requirements Engineering1996，1，2：	1
10	Combretastatin A-4,an agent that displays potent and selective toxicity toward tumor vasculature显示文摘	Dark G G Hill S A Prise V E Tozer G M Pettit G R Chaplin D J	1997	Cancer Res1997，57，：	1
11	Pemetrexed combined with oxaliplatin or carboplatin as furst -line treatment in advanced non- small cell lung cancer:a multicenter,randomized, phase II trial显示文摘	SCAGLIOTTI G V KORTSIK C DARK G G	2005	Clin Cancer Res2005，11，21：	1
12	Pemetrexed- combined with oxaliplatin or carboplatin as first-line treatmentinadvanced non-small cell lung cancer:, a multi- center,randomized, phase Ⅱ trial 显示文摘	Scagliotti G V Kortsik C Dark G G	2005	Clin Cancer Res2005，11，21：	1
13	Bench -to -bedside review: the promise of rapid infection diagnosis during sepsis using polymerase chain reaction -based pathogen detection 显示文摘	Dark PM Dean P Warhurst G	2009	Crit Care2009，13，4：	1
14	Breathing pattern abnormalities and arterial oxygen desaturation during sleep in the congestive Heart failure syndrome:improvement following medical therapy显示文摘	Dark D S Pingleton S K Kerby G R	1987	Chest1987，91，：	1
15	Differentiation and definition of vascular-targeted therapies 显示文摘	Siemann D W Bibby M C Dark G G	2005	Clin Cancer Res2005，11，21：	1
16	Circulating endothelial progenitor cell numbers are not associated with donor organ age or allograft vasculopathy in cardiac transplant recipients 显示文摘	Thomas HE Parry G Dark JH	2009	Atherosclerosis2009，202，2：	1
17	Differentiation and definition of vascular-targeted therapies 显示文摘	SIEMANN D W BIBBY M C DARK G G	2005	Clinical Cancer Research2005，11，2：	1
18	Cardiac measurements on thoracic radiographs of cats显示文摘	Van den Broek A M Darke P G	1987	Journal of the Small Animal Practice1987，28，1：	1
19	Phospholipid hydration studied by deuteron magnetic resonance spectroscorpy显示文摘	Finer E G Darke A	1974	Chem Phys Lipids1974，12，：	1
20	Photoperiodic regulation of body mass food intake and reproduction in meadow voles显示文摘	Dark J Zucker I Wade G N	1983	Am J Physiol Regul Integr Comp Physiol1983，245，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示